Skip to main content
SpringerLink
Log in

Antimicrobial Stewardship in Critically Ill Cancer Patients

  • Reference work entry
  • First Online:
Oncologic Critical Care

  • 93 Accesses

Abstract

Patients with cancer including those that need intensive care develop serious infections often and receive multiple courses of antimicrobial therapy for various indications. Heavy antimicrobial usage creates selection pressures leading to the development of resistant microorganisms. Judicious use of antimicrobial agents (antimicrobial stewardship) in this patient population can reduce the development of resistance and prolong the utility of current and novel agents. Other benefits of antimicrobial stewardship include a reduction in the length of stay in the hospital which is associated with reduced health care costs, as well as fewer treatment-related adverse events. Most institutions now have an antimicrobial stewardship team that helps clinical care providers on a daily basis, using well established strategies to ensure appropriate antimicrobial usage. These teams are multidisciplinary and include participants from Infectious Diseases Service, the Pharmacy, the Clinical Microbiology Laboratory, Infection Control, Hospital Epidemiology, and Hospital Administration. Stewardship strategies include formulary restriction and management, preapproval of selected agents, prospective audit of antimicrobial therapy with real time feedback, antibiotic cycling, and/or heterogeneity, among others. Ongoing educational activities are essential for creating awareness initially and for maintaining interest and continued participation institution wide. Measuring the impact of stewardship on specific outcomes (resistance, costs, etc.) is also important and provides valuable feedback regarding the impact of stewardship at individual institutions. Like Infection Control, institutions are now required to have antimicrobial stewardship programs in place.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 949.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 1,299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Nesher L, Rolston KVI. Infections in patients with cancer. In: Holland-Frei cancer medicine. 9th ed. Hoboken: Wiley/Blackwell; 2017. p. 1865–77.

    Google Scholar 

  2. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228–37.

    Article  Google Scholar 

  3. Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis. 2011;53(8):798–806.

    Article  Google Scholar 

  4. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56–93.

    Article  Google Scholar 

  5. Tverdek FP, Rolston KV, Chemaly RF. Antimicrobial stewardship in patients with cancer. Pharmacotherapy. 2012;32(8):722–34.

    Article  Google Scholar 

  6. Rapoport B, Klastersky J, Raftopoulos H, et al. The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC “Neutropenia, Infection and Myelosuppression” Study Group during the MASCC annual meeting held in Berlin on 27–29 June 2013. Support Care Cancer. 2016;24(7):2819–26.

    PubMed  Google Scholar 

  7. Boucher HW, Talbot GH, Benjamin DK, et al. 10 × ′20 Progress – development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(12):1685–94.

    Google Scholar 

  8. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.

    Article  Google Scholar 

  9. Talbot GH, Jezek A, Murray BE, et al. The Infectious Diseases Society of America’s 10 × ′20 Initiative (ten new systemic antibacterial agents FDA-approved by 2020): is 20 × ′20 a possibility? Clin Infect Dis. 2019 Feb 1: https://doi.org/10.1093/cid/ciz089)

  10. Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–77.

    Article  Google Scholar 

  11. Mihu CN, Rhomberg PR, Jones RN, Coyle E, Prince RA, Rolston KV. Escherichia coli resistance to quinolones at a comprehensive cancer center. Diagn Microbiol Infect Dis. 2010;67(3):266–9.

    Article  CAS  Google Scholar 

  12. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis. 2005;24(2):111–8.

    Article  CAS  Google Scholar 

  13. Montassier E, Batard E, Gastinne T, Potel G, de La Cochetière MF. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013;32(7):841–50.

    Article  CAS  Google Scholar 

  14. Perron T, Emara M, Ahmed S. Time to antibiotics and outcomes in cancer patients with febrile neutropenia. BMC Health Serv Res. 2014;14(1):162.

    Article  Google Scholar 

  15. Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2016;14(7):882–913.

    Article  CAS  Google Scholar 

  16. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(Suppl 5):v111–8.

    Article  CAS  Google Scholar 

  17. Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018;36(14):1443–53.

    Article  Google Scholar 

  18. Mokart D, Saillard C, Sannini A, et al. Neutropenic cancer patients with severe sepsis: need for antibiotics in the first hour. Intensive Care Med. 2014;40(8):1173–4.

    Article  Google Scholar 

  19. Liss BJ, Vehreschild JJ, Cornely OA, et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extendedspectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012;40(6):613–9.

    Article  CAS  Google Scholar 

  20. Nesher L, Rolston KV, Shah DP, et al. Fecal colonization and infection with Pseudomonas aeruginosa in recipients of allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2014;17(1):33–8.

    Article  Google Scholar 

  21. Rolston KV, Nesher L, Mulanovich V, Chemaly R. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2013;41(5):1039–40.

    Article  CAS  Google Scholar 

  22. Foolad F, Nagel JL, Eschenauer G, Patel TS, Nguyen CT. Disease-based antimicrobial stewardship: a review of active and passive approaches to patient management. J Antimicrob Chemother. 2017;72(12):3232–44.

    Article  CAS  Google Scholar 

  23. Robilotti E, Holubar M, Seo SK, Deresinski S. Feasibility and applicability of antimicrobial stewardship in immunocompromised patients. Curr Opin Infect Dis. 2017;30(4):346–53.

    Article  Google Scholar 

  24. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51–77.

    Article  Google Scholar 

  25. Wojenski DJ, Barreto JN, Wolf RC, Tosh PK. Cefpodoxime for antimicrobial prophylaxis in neutropenia: a retrospective case series. Clin Ther. 2014;36(6):976–81.

    Article  CAS  Google Scholar 

  26. Nesher L, Tverdek FP, Mahajan SN, Chemaly RF, Rolston KVI. Ertapenem usage in cancer patients with and without neutropenia: a report on 97 cases from a comprehensive cancer center. Infection. 2015;43(5):545–50.

    Article  CAS  Google Scholar 

  27. Snyder M, Pasikhova Y, Baluch A. Early antimicrobial de-escalation and stewardship in adult hematopoietic stem cell transplantation recipients: retrospective review. Open Forum Infect Dis. 2017;4(4):ofx226.

    Article  Google Scholar 

  28. Klastersky J, Raftopoulos H, Rapoport B. The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia. Support Care Cancer. 2013;21(6):1793–5.

    Article  Google Scholar 

  29. Kern WV. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis. 2006;42(4):533–40.

    Article  Google Scholar 

  30. Elting LS, Lu C, Escalante CP, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol. 2008;26(4):606–11.

    Article  Google Scholar 

  31. Buss BA, Baures TJ, Yoo M, et al. Impact of a multiplex PCR assay for bloodstream infections with and without antimicrobial stewardship intervention at a cancer hospital. Open Forum Infect Dis. 2018;5(10):ofy258.

    Article  Google Scholar 

  32. Seo SK, Lo K, Abbo LM. Current state of antimicrobial stewardship at solid organ and hematopoietic cell transplant centers in the United States. Infect Control Hosp Epidemiol. 2016;37(10):1195–200.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Kenneth V. I. Rolston

  2. Infectious Disease Institute, Soroka Medical Center, Ben-Gurion University of the Negev, Beer-Sheba, Israel

    Lior Nesher

Authors
  1. Kenneth V. I. Rolston
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lior Nesher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth V. I. Rolston .

Editor information

Editors and Affiliations

  1. Department of Critical Care and Respiratory Care, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Joseph L. Nates

  2. Division of Anesthesiology, Critical Care and Pain Medicine, Department of Critical Care and Respiratory Care, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Kristen J. Price

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Rolston, K.V.I., Nesher, L. (2020). Antimicrobial Stewardship in Critically Ill Cancer Patients. In: Nates, J., Price, K. (eds) Oncologic Critical Care. Springer, Cham. https://doi.org/10.1007/978-3-319-74588-6_127

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-74588-6_127

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-74587-9

  • Online ISBN: 978-3-319-74588-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation